AZ’ Calquence granted US Breakthrough Therapy Designation
admin 14th August 2019 Uncategorised 0The drug has been approved for chronic lymphocytic leukaemia.
More: AZ’ Calquence granted US Breakthrough Therapy Designation
Source: News
The drug has been approved for chronic lymphocytic leukaemia.
More: AZ’ Calquence granted US Breakthrough Therapy Designation
Source: News
© 1994 - 2025 B.M. Pharmaceuticals